Keren Zhou1, Diana Isaacs2. 1. Endocrinology and Metabolism Institute, Cleveland Clinic, 9500 Euclid Avenue, F20, Cleveland, OH, 44195, US. zhouk2@ccf.org. 2. Endocrinology and Metabolism Institute, Cleveland Clinic, 9500 Euclid Avenue, F20, Cleveland, OH, 44195, US.
Abstract
PURPOSE OF REVIEW: Closed-loop insulin pump systems (artificial pancreas) represent the cutting edge of insulin delivery technology. There are only a few systems currently approved for use in the USA: the MiniMed 670G/770G (which share an algorithm), t:slim X2 Control IQ, and the Omnipod 5. We review these systems and look into the future of the technology. RECENT FINDINGS: All of the approved closed-loop insulin pump systems have demonstrated in multicenter prospective trials improvements in time in range, hemoglobin A1c, and time spent in hypoglycemia. The newer systems have also improved time spent in automation. Comparisons between the systems with regard to glycemic control are difficult to make due to differences in clinical trial design, but there are notable differences in the user experience between systems. The past few years have been a time of exponential development in the field of closed-loop insulin pump systems. However, more research is needed to provide full automation of these systems without any need for information from the user.
PURPOSE OF REVIEW: Closed-loop insulin pump systems (artificial pancreas) represent the cutting edge of insulin delivery technology. There are only a few systems currently approved for use in the USA: the MiniMed 670G/770G (which share an algorithm), t:slim X2 Control IQ, and the Omnipod 5. We review these systems and look into the future of the technology. RECENT FINDINGS: All of the approved closed-loop insulin pump systems have demonstrated in multicenter prospective trials improvements in time in range, hemoglobin A1c, and time spent in hypoglycemia. The newer systems have also improved time spent in automation. Comparisons between the systems with regard to glycemic control are difficult to make due to differences in clinical trial design, but there are notable differences in the user experience between systems. The past few years have been a time of exponential development in the field of closed-loop insulin pump systems. However, more research is needed to provide full automation of these systems without any need for information from the user.
Authors: Laurel H Messer; Bruce A Buckingham; Fran Cogen; Mark Daniels; Gregory P Forlenza; Rabab Jafri; Nelly Mauras; Andrew Muir; R Paul Wadwa; Perrin White; Steven Russell; Edward R Damiano; Firas El-Khatib; Katrina J Ruedy; Courtney Balliro; Zoey Li; Chase Marak; Peter Calhoun; Roy W Beck Journal: Diabetes Technol Ther Date: 2022-06-28 Impact factor: 7.337
Authors: Michael P Stone; Pratik Agrawal; Xiaoxiao Chen; Margaret Liu; John Shin; Toni L Cordero; Francine R Kaufman Journal: Diabetes Technol Ther Date: 2018-08-30 Impact factor: 6.118
Authors: Gregory P Forlenza; Bruce A Buckingham; Sue A Brown; Bruce W Bode; Carol J Levy; Amy B Criego; R Paul Wadwa; Erin C Cobry; Robert J Slover; Laurel H Messer; Cari Berget; Susan McCoy; Laya Ekhlaspour; Ryan S Kingman; Mary K Voelmle; Jennifer Boyd; Grenye O'Malley; Aimee Grieme; Kaisa Kivilaid; Krista Kleve; Bonnie Dumais; Todd Vienneau; Lauren M Huyett; Joon Bok Lee; Jason O'Connor; Eric Benjamin; Trang T Ly Journal: Diabetes Technol Ther Date: 2021-01-18 Impact factor: 6.118